Upsher-Smith rolls out TORPENZ (everolimus) tablets
Upsher-Smith Launches TORPENZ (everolimus) tablets
Chain Drug Review
Flu and RSV vaccine appointments now available at Rite Aid locations
Rite Aid announces availability of Flu and RSV vaccine appointments at all locations
CVS Health mobilizes its response as Hurricane Debby makes landfall
The pharmacy has implemented numerous measures to mitigate the risk of pauses in prescription fulfillment.
NACDS names Stephanie Katz to advance pharmacy reimbursement priorities
Stephanie Katz will lead reimbursement, innovation, and advocacy alongside Dr. Lauren Lyles-Stolz.
PBMs have their say in Congress; report assails industry
The House Committee on Oversight and Accountability published a report ahead of the hearing slamming PBM practices.
NRF: Economy still growing, but could be slowing enough for fed to lower interest rates this year
“The consumer environment has kept the expansion on a positive path toward a ‘soft landing’ despite high interest rates."
Amazon reports profitable Q2, but offers a cautious outlook for Q3
Amazon on Thursday reported strong sales and improved profits in its fiscal second quarter, but the company's stock price fell in after-hours trading after the company noted that sales and profits may fall somewhat in the third quarter.
WBA sells shares of Cencora for about $1.1 billion of proceeds
The stock sale has no impact to the long-term partnership between the two companies.
NACDS receives 2024 Power of Associations Silver Award
The National Association of Chain Drug Stores (NACDS) has been named a 2024 Power of Associations Silver Award winner by the American Society of Association Executives (ASAE) for its “Expanding Access to Food is Medicine Through Pharmacies” initiative.
Good Neighbor Pharmacy tops J.D. Power’s Satisfaction Index among chain drug pharmacies
Good Neighbor Pharmacy (GNP), a national franchise for independent pharmacies offered through Cencora, has been ranked “#1 in Customer Satisfaction with Chain Drug Store Pharmacies” in the J.D. Power 2024 U.S. Pharmacy Study, the company said.
